Nova Eye Medical : Evans & Partners Small Cap Healthcare Conference Presentation

Addressing the Leading Causes of Blindness

Nova Eye Medical Limited (ASX:EYE)

Evans & Partners Small Cap Healthcare Conference

September 2023

Disclaimer

This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward- looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medical (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.

nova-eye.com| 2

Business Snapshot

Nova Eye Medical leads the way in interventional treatment solutions for glaucoma and age-related macular degeneration (AMD), the leading causes of blindness in the developed world.

Nova Eye Medical, Glaucoma

Strategy	Develop, market and sell comprehensive portfolio
of glaucoma consumable surgical devices
Market	Canaloplasty segment of the glaucoma surgical
devices market scheduled to grow rapidly 2022-27
Sales	Established infrastructure; direct sales in USA,
Germany, Australia; +20 distributors
Manufacturing	California, USA and Dunedin, New Zealand
IP Status	>100 patents issued and pending
Regulatory	Clearance in all key global markets, including USA
(FDA)
Reimbursement	Favorable CPT codes (USA)

AlphaRET, AMD

Strategy	Commercialise 2RT® to technology with
partner
	Intermediate Age-related Macular
Market	Degeneration treatment (iAMD) - market
not addressed. Underserved market for
	retinal disease therapy
Sales	Sales program to coincide with partnering
Manufacturing	Adelaide, Australia based contract
manufacturing
IP Status	First mover advantage, >10 patents issued
and pending in major markets
	CE Mark (iAMD and diabetic eye disease)
Regulatory	in Europe, Australia, NZ. FDA USA
	clearance for diabetic eye disease

nova-eye.com| 3

Company Overview

Capital Structure
ASX Code	EYE
Share Price (at 7 September 2023)	$0.195

Share Price Chart

6,000,000		$0.35

Shares on Issue	190	M
Unlisted Options	3.35	M
Market Capitalisation	$37.16 M
Cash	$7.54M
Top 20 Shareholders	51%

5,000,000

4,000,000

3,000,000

2,000,000

1,000,000

$0.30

$0.25

$0.20

$0.15

Shareholders

Significant shareholder support from the top 20 shareholders

49%

Top 20 Shareholders

51% Others

0

$0.10

15-Jul-2022

29-Jul-2022

12-Aug-2022

26-Aug-2022

14-Jul-2023

28-Jul-2023

1-Jul-2022

9-Sep-2022

23-Sep-2022

7-Oct-2022

21-Oct-2022

4-Nov-2022

18-Nov-2022

2-Dec-2022

16-Dec-202230-Dec-202213-Jan-2023

27-Jan-2023

10-Feb-2023

24-Feb-202310-Mar-202324-Mar-20237-Apr-202321-Apr-2023

5-May-2023

19-May-2023

2-Jun-2023

16-Jun-2023

30-Jun-2023

11-Aug-2023

25-Aug-2023

Volume

Share Price

nova-eye.com| 4 nova-eye.com| 4

FY23 Achievements

Strong Financial Results with Record Global Sales

Record	Substantial lift in
global sales	gross margin to	Cash on hand
US$11.3m	73%	A$7.4m
for the glaucoma surgical	compared to 60%	at 30 June 2023 to
devices segment	in the first half FY23	support growth

nova-eye.com| 5